Clinical features of GT and PEG-ADA treated patients at the time of analysis
| Patients . | Age, y . | Follow-up, y . | Autoimmunity . | T cells, counts/μL . | dAXP, μmol . | |
|---|---|---|---|---|---|---|
| CD3 . | CD4 . | |||||
| GT (n = 11) | 4.5 (1.5-10.8) | 3 (1-8.5) | 1 patient with hypothyroidism | 848 (452-2911) | 410 (121-709) | 15 (0-84) |
| PEG-ADA (n = 7) | 12.1 (0.6-23) | 13 (0.5-21.2) | 1 patient with type I diabetes | 1489 (71-4599) | 671 (35-1653) | 4 (0-74) |
| Patients . | Age, y . | Follow-up, y . | Autoimmunity . | T cells, counts/μL . | dAXP, μmol . | |
|---|---|---|---|---|---|---|
| CD3 . | CD4 . | |||||
| GT (n = 11) | 4.5 (1.5-10.8) | 3 (1-8.5) | 1 patient with hypothyroidism | 848 (452-2911) | 410 (121-709) | 15 (0-84) |
| PEG-ADA (n = 7) | 12.1 (0.6-23) | 13 (0.5-21.2) | 1 patient with type I diabetes | 1489 (71-4599) | 671 (35-1653) | 4 (0-74) |
Data are median (range).
dAXP indicates deoxyadenosine nucleotides in RBCs.